Perfuze Receives FDA 510(k) Clearance for Zipline™ Access Catheters and Secures €22M in Additional Funding
GALWAY, Ireland, March 13, 2025--(BUSINESS WIRE)--Perfuze, a leading medical device company dedicated to advancing stroke treatment, today announced that it has received FDA 510(k) clearance for its Zipline™ Access Catheters. This regulatory milestone strengthens Perfuze's growing portfolio of innovative neurovascular devices, empowering physicians to treat acute ischemic strokes with greater speed, ease, and precision. In addition, Perfuze has secured €22 million in follow-on funding in a round led by existing investors including Earlybird, EQT Life Sciences, Seroba and SV Health.
Transforming Stroke Care with Zipline™
Every minute counts in stroke care. As a stroke progresses, human brain tissue is quickly and permanently lost, making urgent therapeutic intervention critical. The Zipline™ Access Catheters are engineered to enhance the trackability and delivery of large (070) and superbore (088) aspiration catheters, simplifying neurointerventional procedures and enabling faster, more efficient stroke treatment. By providing increased support and navigational ease, Zipline™ aims to optimize clot removal efficiency, ultimately improving procedural success rates and patient outcomes. The FDA clearance marks a significant step forward in Perfuze's mission to simplify and improve stroke treatment and outcomes through technological innovation.
"The FDA clearance of our Zipline™ Access Catheter is a testament to Perfuze's commitment to developing best-in-class stroke solutions," said Wayne Allen, CEO of Perfuze. "This regulatory approval strengthens our growing presence in the U.S. market and supports our vision of delivering novel, effective, and easy-to-use technologies that can make a real difference in stroke care." Dr. Jay Dolia, Assistant Professor, Neurology, Emory University School of Medicine stated: "The Zipline catheters represent an innovative technology that I believe will simplify stroke intervention, reduce costs and accelerate reperfusion. In my initial experience, they have enabled rapid clot access and aspiration, even in complex anatomy."
Fueling Growth: €22 Million Investment to Drive Commercial Rollout
Perfuze has successfully closed a €22 million funding round, led by existing investors. This investment will support the Limited Market Release of the Zipline™ and Millipede™ catheters while advancing ongoing clinical and R&D initiatives to further enhance stroke treatment capabilities.
Perfuze has initiated a Limited Market Release in the U.S. in prestigious US Comprehensive Stroke Centres. The company's growing portfolio is designed to provide physicians with highly effective tools to simplify stroke treatment and improve patient outcomes. "The continued support from our investors underscores the confidence in Perfuze's technology and vision," stated Perfuze Chairperson, Hooman Hakami. "With this funding, we are well-positioned to initiate our U.S. Limited Market Release and drive adoption in select centers of our transformative stroke treatment solutions."
For more information about Perfuze and its innovative stroke treatment solutions, visit www.perfuze.com.
About Perfuze
Perfuze is a medical device company headquartered in Galway, Ireland, dedicated to developing next-generation catheter-based aspiration technology for the treatment of acute ischemic stroke. The company's proprietary platform is designed to maximize clot removal efficiency, enhance procedural simplicity, and improve clinical outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313532644/en/
Contacts
Media Contact: Freskida GoniCommunications Consultant Perfuzefreskida.goni@gmail.com +44 7473678178
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
VideoAmp Launches THE REPLAY Revealing New Insights Into Live Sports Audiences
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Today, VideoAmp is debuting a new monthly insights report called THE REPLAY – an interactive analysis of television viewership across major sports tentpole events. Each edition of THE REPLAY will explore the nuances of viewing behavior, regional loyalty, and audience segmentation that shape how America tunes in at home and in public venues leveraging VideoAmp's out-of-home measurement tools. VideoAmp's out-of-home measurement examines whether fans gathered in public venues or stayed home for the big game. Powered by VideoAmp's VALID™ big data and tech engine, THE REPLAY delivers advanced audience ratings and household-level insights in a highly visual and interactive public-facing tool. "For media companies and advertisers alike, THE REPLAY will become a must-use tool for decision-making," said Peter Liguori, Executive Chairman of VideoAmp. "This isn't simply a monthly data dump. Our experts and analysts will be providing an unprecedented and thoughtful look at sports media consumption, and the unique moments when brands can reach passionate, highly engaged viewers that only VideoAmp's advanced audience capabilities make possible." The first edition of THE REPLAY looks back on this year's March Madness, examining how fans watched and where their loyalties shifted. From out-of-home spikes to changing regional dynamics, behavior evolved each round. For example, this month's edition found that during the later rounds of the tournament, the audience included a higher share of top investor households (having at least $100K in invested assets) and those with high discretionary income (HHs $200K). The March 30th Michigan v Auburn game and all the Final Four games including the Championship saw over 1m+ $200k households tune in. The next edition, coming in early July, will highlight the NBA Finals with future months set to explore The Stanley Cup Finals, the NFL season opener and the US Open. In 2024, 75 of the top 100 programs in terms of live audience were sports programming. Streamers know this, and are increasingly investing more in the space. Emarketer recently published a report that projected that over 105 million U.S. viewers watched live sports digitally in 2024, an increase from 95.5 million during the previous year. That same report expects digital viewing of live sports will reach 127.4 million viewers in the U.S., a 21% increase from 2024. About VideoAmp VideoAmp is a media measurement company transforming advertising. By leveraging the power of currency-grade big data, VideoAmp's solutions provide clients with access to advanced audiences and the ability to precisely plan, optimize and measure media investments across platforms to achieve better outcomes. With these solutions, media sellers can increase the value of their inventory, while advertisers can benefit from increased return on investment. VideoAmp has seen incredible adoption for its measurement and currency solutions with 880% YoY growth, 98% coverage of the TV publisher ecosystem, 11 agency groups and more than 1,000+ advertisers. VideoAmp is headquartered in Los Angeles and New York with offices across the United States. To learn more, visit View source version on Contacts Media Contact:Cassady NordeenCassady@ Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
CORRECTING and REPLACING Smart Meter Selected By 9amHealth for Major Employer Weight Management Programs Using Cellular Weight Scale
TAMPA, Fla., June 13, 2025--(BUSINESS WIRE)--Please replace the release dated June 11, 2025 with the following corrected version due to multiple revisions. The updated release reads: SMART METER SELECTED BY 9AMHEALTH FOR MAJOR EMPLOYER WEIGHT MANAGEMENT PROGRAMS USING CELLULAR WEIGHT SCALE Smart Meter, a pioneer in cellular-enabled weight scale technology, today announced a strategic supply agreement with 9amHealth, a leading provider of comprehensive weight management and cardiometabolic benefits for large employers. This collaboration integrates Smart Meter's advanced cellular weight scales into 9amHealth's multi-disciplinary care platform, delivering real-time health data and enhanced outcomes for employees at major technology companies and Fortune 500 organizations. Addressing Critical Gaps in Employee Weight Management for Millions of Americans The partnership addresses a significant challenge identified by leading employers: while lifestyle changes remain the foundation of managing weight, traditional approaches often lack the consistent monitoring and data integration required to achieve and maintain goals. With major tech companies already deploying 9amHealth's solution, the addition of Smart Meter's cellular scales provides seamless, automatic data collection that eliminates barriers to consistent tracking. "We're seeing tremendous demand from large employers who want to move beyond BMI-only assessments and provide their employees with easy-to-use technology to support better weight management," said Casey Pittock, CEO at Smart Meter. "Our cellular scales integrate perfectly with 9amHealth's clinical approach, providing real-time data that allows physicians, pharmacists, and dietitians to deliver personalized care." Enhancing Clinical Care with Real-Time Data 9amHealth's evidence-based program combines physicians, pharmacists, and registered dietitians trained in obesity care, available virtually across all 50 states. The integration of Smart Meter's cellular scales enhances this care model by: Automatic Data Transmission: Eliminating the need for manual weight logging, reducing friction in the patient experience Real-Time Clinical Insights: Enabling care teams to monitor progress and adjust treatment plans promptly Comprehensive Metabolic Monitoring: Supporting early identification of conditions like prediabetes and diabetes Seamless Integration: Connecting directly with 9amHealth's clinical platform without requiring additional apps or devices "Nearly 10% of new members enrolling in our weight health and cardiometabolic program are found to have previously undiagnosed prediabetes or diabetes," said Dr. Avantika Waring, MD, Chief Medical Officer at 9amHealth. "Smart Meter's cellular scales give us consistent, reliable data that supports early identification of risk patterns and enables more personalized interventions—focused on improving overall health, not just weight loss." Breaking Down Barriers to Participation The device, data, and service agreement specifically addresses socioeconomic challenges that have historically limited participation in employer weight management programs. By removing the complexity of manual tracking and providing technology that works regardless of geographic location, the solution serves remote populations with varying: Cultural preferences around health monitoring Technical comfort levels Geographic limitations Previous experiences with weight management programs Proven Results with Major Technology Companies Leading technology companies have already implemented 9amHealth's comprehensive program, recognizing weight care as an entry point to broader health support for employees with comorbidities. The addition of Smart Meter's cellular scales strengthens these deployments by providing: Consistent engagement through automated tracking Reduced administrative burden on HR teams Enhanced clinical outcomes through better data quality Improved employee satisfaction through simplified user experience Meeting Employees Where They Are Unlike traditional programs that require employees to repeat previous lifestyle interventions before accessing additional care, the 9amHealth solution meets each person where they are in their health journey. Smart Meter's Cellular scales support this philosophy by providing immediate, judgment-free data collection that integrates seamlessly with comprehensive care plans ranging from lifestyle coaching to GLP-1 prescriptions and bariatric surgery referrals when appropriate. About Smart Meter, LLC Smart Meter is the trusted supplier of Remote Patient Monitoring ("RPM") solutions. The company's technology and services empower a nationwide network of SmartPartnersTM who are working directly with healthcare providers to transform patient care. Millions of vital health data readings are reliably delivered across the company's secure platform to enable real-time, better-informed health care. The company's proprietary patient-friendly cellular FDA-registered monitoring devices are connected to an exclusive AT&T 4/5G network to ensure an engaging patient experience for improved adherence. For more information, visit About 9amHealth 9amHealth offers complete cardiometabolic care—a first-of-its-kind, whole-body approach to preventing and treating obesity, diabetes, high cholesterol, and hypertension. They partner with employers, health plans, and PBMs to provide effective health benefits for those living with chronic conditions. Their members receive personalized care plans, prescription delivery, at-home lab tests, and unlimited specialist access. 9amHealth was founded in 2021 by the team behind mySugr and is backed by 7Wire Ventures, Cigna Ventures, Human Capital, Founders Fund, and Define Ventures. Learn more at View source version on Contacts Media Contact Keith 336-509-8024 Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
